Extreme founder effect in an HIV type 1 subtype A epidemic among drug users in Svetlogorsk, Belarus.
Lukashov
V V
VV
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, The Netherlands.
Karamov
E V
EV
Eremin
V F
VF
Titov
L P
LP
Goudsmit
J
J
D000293:Adolescent; D000328:Adult; D000595:Amino Acid Sequence; D004196:Disease Outbreaks; D018703:Founder Effect; D015683:Gene Products, gag / Q000235:genetics; D016655:HIV Core Protein p24 / Q000235:genetics; D015699:HIV Envelope Protein gp120 / Q000235:genetics; D015658:HIV Infections / Q000453:epidemiology* / Q000821:virology*; D015497:HIV-1 / Q000145:classification* / Q000302:isolation & purification*; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics; D002094:Republic of Belarus / Q000453:epidemiology; D017422:Sequence Analysis, DNA; D015819:Substance Abuse, Intravenous
D015683:Gene Products, gag; D016655:HIV Core Protein p24; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments